Depo-Provera (DP) and Generic Equivalent (DMPA) Investigated by Federman & Sherwood

Oklahoma City, OK (April 11, 2025) – Federman & Sherwood, a nationally recognized class-action litigation firm with offices in Oklahoma City and Dallas, has launched an investigation into the potential health risks associated with the use of Depo-Provera (DP) and its generic equivalent, Depot Medroxyprogesterone Acetate (DMPA). These medications are widely prescribed as injectable birth control and are also used to regulate menstrual cycles. In higher doses, they may also be administered to treat certain forms of cancer.

Recent medical findings have raised serious concerns that the use of DP and DMPA may be linked to the development of brain tumors, including meningiomas—a type of tumor that arises from the membranes surrounding the brain and spinal cord. This emerging evidence has prompted legal action, with lawsuits now being pursued to secure compensation for affected individuals, including claims for medical monitoring, treatment costs, and other financial damages.

Federman & Sherwood is dedicated to advocating for women who may have been harmed by these medications. The firm is actively reviewing claims on behalf of those who have used Depo-Provera or its generic equivalent and experienced adverse health effects, particularly related to neurological symptoms or tumor diagnoses.

If you or someone you know has used Depo-Provera (DP) or DMPA, it is important to understand your legal rights and whether you may be eligible for compensation.

To learn more about this investigation, discuss your potential claim, or participate in the litigation, please contact Tashia Poore by email at tdp@federmanlaw.com or visit the firm’s website at www.federmanlaw.com.

FEDERMAN & SHERWOOD

(405) 235-1560